---
figid: PMC6050811__10.1177_1758835918786451-fig1
figlink: /pmc/articles/PMC6050811/figure/fig1-1758835918786451/
number: F1
caption: 'The role of the cyclin D1–CDK4/6–RB pathway in breast cancer.The role of
  the cyclin D1–CDK4/6-RB pathway in breast cancer cells, including cross talk with
  other oncogenic signaling pathways. Mitogenic forces including ER transcriptional
  activity and signaling through ERBB2/PI3K/AKT/mTOR increase cyclin D1 levels, activating
  CDK4/6 and promoting cellular progression to the S phase. There is extensive crosstalk
  between the PI3K and CDK4/6 pathways: not only does PI3K pathway activity increase
  cyclin D1 levels, but the cyclin D–CDK4/6 complex can modulate TSC2 phosphorylation
  and hence mTORC1 activity. Combined inhibition of CDK4/6 and nodes in the PI3K pathway
  can thus maximally suppress mTORC1 activity as well as RB phosphorylation, inhibiting
  two promoters of S phase progression. Furthermore, suppression of E2F activity can
  modulate the tumor cell epigenome, rendering tumor cells more immunogenic and providing
  a rationale for CDK4/6-immunotherapy combinations.AR, androgen receptor; EGFR, epidermal
  growth factor receptor; ER, estrogen receptor; HER, human epidermal growth factor
  receptor; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide-3-kinase;
  RB, retinoblastoma protein, TSC2, tuberous sclerosis complex 2 (tuberin).'
pmcid: PMC6050811
papertitle: 'CDK4/6 inhibition in breast cancer: current practice and future directions.'
reftext: Sonia Pernas, et al. Ther Adv Med Oncol. 2018;10:1758835918786451.
pmc_ranked_result_index: '25926'
pathway_score: 0.9462694
filename: 10.1177_1758835918786451-fig1.jpg
figtitle: The cyclin D1–CDK4/6–RB pathway in breast cancer.The role of the cyclin
  D1–CDK4/6-RB pathway in breast cancer cells, including cross talk with other oncogenic
  signaling pathways
year: '2018'
organisms:
- Homo sapiens
ndex: 0aaa77f3-dea7-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6050811__10.1177_1758835918786451-fig1.html
  '@type': Dataset
  description: 'The role of the cyclin D1–CDK4/6–RB pathway in breast cancer.The role
    of the cyclin D1–CDK4/6-RB pathway in breast cancer cells, including cross talk
    with other oncogenic signaling pathways. Mitogenic forces including ER transcriptional
    activity and signaling through ERBB2/PI3K/AKT/mTOR increase cyclin D1 levels,
    activating CDK4/6 and promoting cellular progression to the S phase. There is
    extensive crosstalk between the PI3K and CDK4/6 pathways: not only does PI3K pathway
    activity increase cyclin D1 levels, but the cyclin D–CDK4/6 complex can modulate
    TSC2 phosphorylation and hence mTORC1 activity. Combined inhibition of CDK4/6
    and nodes in the PI3K pathway can thus maximally suppress mTORC1 activity as well
    as RB phosphorylation, inhibiting two promoters of S phase progression. Furthermore,
    suppression of E2F activity can modulate the tumor cell epigenome, rendering tumor
    cells more immunogenic and providing a rationale for CDK4/6-immunotherapy combinations.AR,
    androgen receptor; EGFR, epidermal growth factor receptor; ER, estrogen receptor;
    HER, human epidermal growth factor receptor; mTOR, mammalian target of rapamycin;
    PI3K, phosphoinositide-3-kinase; RB, retinoblastoma protein, TSC2, tuberous sclerosis
    complex 2 (tuberin).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CDK4
  - E2F6
  - AR
  - CYP19A1
  - ERBB3
  - MTOR
  - AKT2
  - TSC2
  - PIK3CB
  - PIK3CD
  - CDK6
  - AKT1
  - CCND1
  - EGFR
  - PIK3R3
  - RPTOR
  - E2F2
  - E2F3
  - PIK3CG
  - E2F1
  - ERBB2
  - RPS6KB1
  - E2F8
  - AKT3
  - PIK3R4
  - PIK3CA
  - PIK3R5
  - E2F7
  - E2F5
  - PIK3R6
  - E2F4
  - RPS6KB2
  - lapatinib
  - neratinib
  - Letrozole
  - anastrozole
  - Estradiol
  - exemestane
  - Tamoxifen
  - fulvestrant
  - buparlisib
  - Everolimus
  - Cancer
genes:
- word: CDK4/6
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F6
  entrez: '1876'
- word: AR
  symbol: AR
  source: hgnc_symbol
  hgnc_symbol: AR
  entrez: '367'
- word: Aromatase
  symbol: aromatase
  source: hgnc_alias_symbol
  hgnc_symbol: CYP19A1
  entrez: '1588'
- word: EGFR/HER2/HER3
  symbol: HER3
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: TSC2
  symbol: TSC2
  source: hgnc_symbol
  hgnc_symbol: TSC2
  entrez: '7249'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: MTORC1,
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: CDK4/6
  symbol: CDK6
  source: hgnc_symbol
  hgnc_symbol: CDK6
  entrez: '1021'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: CyclinD1
  symbol: Cyclin-D1
  source: bioentities_symbol
  hgnc_symbol: CCND1
  entrez: '595'
- word: EGFR/HER2/HER3
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: MTORC1,
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F2
  entrez: '1870'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F3
  entrez: '1871'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F1
  entrez: '1869'
- word: EGFR/HER2/HER3
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: P70S6K
  symbol: P70S6K
  source: bioentities_symbol
  hgnc_symbol: RPS6KB1
  entrez: '6198'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F8
  entrez: '79733'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F7
  entrez: '144455'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F5
  entrez: '1875'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F4
  entrez: '1874'
- word: P70S6K
  symbol: P70S6K
  source: bioentities_symbol
  hgnc_symbol: RPS6KB2
  entrez: '6199'
chemicals:
- word: lapatinib
  source: MESH
  identifier: C490728
- word: neratinib
  source: MESH
  identifier: C487932
- word: Letrozole
  source: MESH
  identifier: C067431
- word: anastrozole
  source: MESH
  identifier: C090450
- word: Estradiol
  source: MESH
  identifier: D004958
- word: exemestane
  source: MESH
  identifier: C056516
- word: Tamoxifen
  source: MESH
  identifier: D013629
- word: fulvestrant
  source: MESH
  identifier: C070081
- word: buparlisib
  source: MESH
  identifier: C571178
- word: Everolimus
  source: MESH
  identifier: C107135
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC6050811__F1
redirect_from: /figures/PMC6050811__F1
figtype: Figure
---
